Company research / ERNA

Ernexa Therapeutics Inc. (ERNA)

CIK 0000748592 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2024-12-31, Ernexa Therapeutics Inc. reported revenue of $582.0K. Revenue grew 755.9% from the prior annual period.

Key ratios (year ended 2024-12-31)

83.5%
Gross margin
-2693.1%
Operating margin
-7652.7%
Net margin
-2618.4%
Return on year-end equity
755.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4 · 2026-09-01

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.